Skip to main content
. 2021 Jun 11;11:639177. doi: 10.3389/fcimb.2021.639177

Figure 3.

Figure 3

Effects of pre-treating Vero E6 cells in cells with different ARBs on the SARS-CoV-2 production. (A) Schematic flow of the analysis: Vero E6 cells were treated with different non-cytotoxic concentrations of ARBs (Azilsartan 15µM; Eprosartan 30µM; Irbesartan 60µM; Losartan 7µM; Olmesartan 15µM; Telmisartan 7µM; Valsartan 7µM) were previously defined by the MTT assay and cells were treated with the different ARBs.) for 72 hours and were subsequently infected and produced virus evaluated by RT-qPCR and Western Blotting 24 hours post-infection (h.p.i.). (B) Relative SARS-CoV-2 genome quantification in supernatant of treated and infected Vero E6 cells by RT-qPCR: Relative viral quantification was performed compared to the untreated control (viruses without drugs) using the 2(–ΔCT) method, where ΔCt = {[(Ct 48 h.p.i) treated well] – [mean (Ct 0 h.p.i)]}; (C) Viral protein detection in treated and infected Vero E6 cells by Western Blotting performed in JessTM Simple Western system (automated Western immunoblotting), in which every column represents individual runs (D) TCID50 (six days post-infection) from the supernatant of the treated with different ARBs Vero E6 cells recovered 24 h.p.i. *P < 0.05; **P < 0.01; ***P < 0.001.